S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:AVIR

Atea Pharmaceuticals Stock Forecast, Price & News

$29.25
+1.11 (+3.94 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$28.43
Now: $29.25
$30.10
50-Day Range N/A
52-Week Range
$24.15
Now: $29.25
$36.65
Volume136,880 shs
Average Volume517,812 shs
Market Capitalization$2.36 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. It also develops AT-787 which is under phase 2 clinical for the treatment of hepatitis C virus; AT-752 which is under phase 2 clinical trial for the treatment of dengue; and AT-889, AT-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. The company was incorporated in 2012 and is based in Boston, Massachusetts.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.08 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVIR
CUSIPN/A
CIKN/A
Phone857 284 8891
Employees11

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$2.36 billion
Next Earnings DateN/A
OptionableNot Optionable
$29.25
+1.11 (+3.94 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AVIR News and Ratings via Email

Sign-up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Atea Pharmaceuticals (NASDAQ:AVIR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Atea Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Atea Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Atea Pharmaceuticals?

Wall Street analysts have given Atea Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Atea Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for AVIR?

4 brokerages have issued twelve-month target prices for Atea Pharmaceuticals' shares. Their forecasts range from $45.00 to $60.00. On average, they anticipate Atea Pharmaceuticals' share price to reach $51.33 in the next year. This suggests a possible upside of 75.5% from the stock's current price.
View analysts' price targets for Atea Pharmaceuticals
.

Who are some of Atea Pharmaceuticals' key competitors?

Who are Atea Pharmaceuticals' key executives?

Atea Pharmaceuticals' management team includes the following people:
  • Dr. Jean-Pierre Sommadossi Ph.D., Founder, Chairman, CEO & Pres (Age 64, Pay $560k)
  • Ms. Andrea J. Corcoran, CFO, Exec. VP of Legal & Sec. (Age 58, Pay $365k)
  • Mr. Wayne Foster C.P.A., CPA, Sr. VP of Fin. & Admin. (Age 52)
  • Mr. Steven Good, Exec. VP of Preclinical Science
  • Mr. Adel Mousa Ph.D., Exec. VP of Chemistry
  • Mr. Xiao-Jian Zhou Ph.D., Exec. VP of Early Stage Devel.
  • Mr. John F. Vavricka, Chief Commercial Officer (Age 56)
  • Dr. Janet M.J. Hammond, Chief Devel. Officer (Age 60)
  • Dr. Maria Arantxa Horga M.D., Acting Chief Medical Officer & Exec. VP of Clinical Sciences (Age 51)

When did Atea Pharmaceuticals IPO?

(AVIR) raised $253 million in an initial public offering on Friday, October 30th 2020. The company issued 11,000,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair served as the underwriters for the IPO.

What is Atea Pharmaceuticals' stock symbol?

Atea Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVIR."

When does the company's quiet period expire?

Atea Pharmaceuticals' quiet period expires on Wednesday, December 9th. Atea Pharmaceuticals had issued 12,500,000 shares in its initial public offering on October 30th. The total size of the offering was $300,000,000 based on an initial share price of $24.00. During the company's quiet period, insiders and underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Atea Pharmaceuticals?

Shares of AVIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Atea Pharmaceuticals' stock price today?

One share of AVIR stock can currently be purchased for approximately $29.25.

How big of a company is Atea Pharmaceuticals?

Atea Pharmaceuticals has a market capitalization of $2.36 billion. Atea Pharmaceuticals employs 11 workers across the globe.

What is Atea Pharmaceuticals' official website?

The official website for Atea Pharmaceuticals is www.ateapharma.com.

How can I contact Atea Pharmaceuticals?

The company can be reached via phone at 857 284 8891 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.